Technical Analysis for SLN - Silence Therapeutics Plc

Grade Last Price % Change Price Change
D 543.0 -1.27% -7.00
SLN closed down 1.27 percent on Friday, April 16, 2021, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical SLN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Walk Weakness -1.27%
Slingshot Bearish Bearish Swing Setup 1.88%
Stochastic Buy Signal Bullish 1.88%
Lower Bollinger Band Walk Weakness 1.88%
Lower Bollinger Band Touch Weakness 1.88%
Oversold Stochastic Weakness 1.88%
Older End-of-Day Signals for SLN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Silence Therapeutics Plc Description

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetic toolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types. The Company's RNA interference (RNAi) platform is AtuRNAi. AtuRNAi is based on specific small interfering RNA (siRNA) modules, stabilization technology and other tailored features. The Company's technology is in the clinic in a Phase IIa pancreatic cancer trial. The Company has developed modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutic RNA molecules.


Sector: Healthcare
Industry: Biotechnology
Keywords: Research Pharmaceutical Clinic Cancer Branches Of Biology IPO Biology Tailor Molecular Biology Pharmaceutical Products Sms Genetics Organs Molecular Genetics Therapeutic Effect

Is SLN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 668.0
52 Week Low 330.0
Average Volume 48,604
200-Day Moving Average 487.86
50-Day Moving Average 577.46
20-Day Moving Average 554.75
10-Day Moving Average 546.50
Average True Range 28.07
ADX 14.87
+DI 17.70
-DI 19.53
Chandelier Exit (Long, 3 ATRs ) 515.79
Chandelier Exit (Short, 3 ATRs ) 576.51
Upper Bollinger Band 591.86
Lower Bollinger Band 517.64
Percent B (%b) 0.34
BandWidth 13.38
MACD Line -10.35
MACD Signal Line -8.79
MACD Histogram -1.5658
Fundamentals Value
Market Cap 450.32 Million
Num Shares 82.9 Million
EPS -25.30
Price-to-Earnings (P/E) Ratio -21.46
Price-to-Sales 243.47
Price-to-Book 12.73
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 557.27
Resistance 3 (R3) 557.85 553.68 554.89
Resistance 2 (R2) 553.68 550.05 553.39 554.09
Resistance 1 (R1) 548.34 547.80 546.26 547.76 553.30
Pivot Point 544.17 544.17 543.13 543.88 544.17
Support 1 (S1) 538.83 540.54 536.75 538.25 532.70
Support 2 (S2) 534.66 538.29 534.37 531.91
Support 3 (S3) 529.32 534.66 531.11
Support 4 (S4) 528.74